GSK has agreed to acquire full global rights to a potential best-in-class trispecific T-cell engager from Chimagen Biosciences in a transaction worth up to $750 million, expanding the pharmaceutical ...

Sept 15 (Reuters) - GSK said on Tuesday it had agreed a deal worth up to $750 million to buy a trispecific T cell-engager (TCE), a drug designed to help T-cells target cancer, from China-based ...

GSK plc GSK has entered into an agreement to acquire an investigational trispecific T-cell engager (TCE) from Chimagen ...

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

GSK (NYSE:GSK) is accelerating investment in research and development, expanding its late-stage pipeline and targeting cost ...

MediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate (ADC). The small cell lung cancer (SCLC) trial hit its primary endpoint, although the B7-H3-dire ...

Companies are responding to patent cliffs and the increased cost of research and development for more complex products.

ORLANDO, Fla. — It was an emotional day for many across Central Florida, and even outside of it, as the city of Orlando began to demolish Pulse nightclub. Contractors arrived on site a little before 7 ...

Welcome to Fierce Biotech’s fifth annual layoff tracker, a resource designed to keep pace with the sector’s steady stream of workforce reductions. In 2025, industry layoffs continued to rise year over ...

A University of Denver study highlights how post-pandemic housekeeping policies have led to main hotel areas becoming dirtier. Online commenters go viral by renaming convenience stores "inconvenience ...